PT  - JOURNAL ARTICLE
AU  - Iaccarino, Antonino
AU  - Pisapia, Pasquale
AU  - Pepe, Francesco
AU  - Sgariglia, Roberta
AU  - Nacchio, Mariantonia
AU  - Russo, Gianluca
AU  - Gragnano, Gianluca
AU  - De Luca, Caterina
AU  - Troncone, Giancarlo
AU  - Malapelle, Umberto
TI  - Liquid biopsy for <em>BRAF</em> mutations testing in non-small cell lung cancer: a retrospective study
AID  - 10.1136/jclinpath-2020-207107
DP  - 2022 Jan 01
TA  - Journal of Clinical Pathology
PG  - 58--60
VI  - 75
IP  - 1
4099  - http://jcp.bmj.com/content/75/1/58.short
4100  - http://jcp.bmj.com/content/75/1/58.full
SO  - J Clin Pathol2022 Jan 01; 75
AB  - V-Raf murine sarcoma viral oncogene homolog B (BRAF) gene mutations have recently been approved to select advanced stages non-small cell lung cancer (NSCLC) patients for tyrosine kinase inhibitors treatments. In this setting, liquid biopsy may represent a valuable option for BRAF mutational testing in patients without tissue availability. Here, we reviewed 196 plasma based liquid biopsies analysed by an in-house developed next generation sequencing panel, termed SiRe. On the overall, 6 (3.1%) out of 196 BRAF mutated cases were identified, with an overall median allelic frequency of 3.4%. Exon 15 p.V600E was the most common detected mutation (2/6, 33.3%). Our data highlighted that the SiRe panel is a robust tool for BRAF mutation assessment on circulating tumour DNA. Further investigation is required to develop a diagnostic algorithm to harmonise BRAF testing on tissue and blood in advanced stages NSCLC patients.